University of Dundee aids AI research for hypertension

pharmafile | March 29, 2023 | News story | Medical Communications  

The University of Dundee has announced its involvement in a Europe-wide project which will study whether AI can improve the outcomes of hypertension (HT) patients by identifying the endocrine HT patients sooner and improving treatment.


HT-ADVANCE is an EU HORIZON project which will span six years and cost €8m. It will look at how AI can improve the identification of secondary ‒ or ‘endocrine’ ‒ hypertension and find better treatments for primary hypertension. HI-ADVANCE will combine multi-omics technologies with machine learning (ML) to find diagnostic biomarkers in blood and urine.


UK Research and Innovation (UKRI) has allocated £2.1m in funding to Dundee, which will develop a clinical tool based on an AI predictor created by the University team in a previous project.


Dr Christian Cole, from the University’s School of Medicine Health Informatics Centre (HIC), said, “Arterial hypertension is not controlled or is poorly controlled in more than half of patients. When such a vast number of people have high blood pressure and when it is linked to so many serious health conditions, the potential for real harm is significant. Getting the right treatment to patients sooner would dramatically improve outcomes for them, and so by taking the HIC-developed machine learning predictor and making it applicable for clinical settings using HIC’s secure infrastructure, we hope to do just that. Clinical trials will then test the algorithm to determine whether it is indeed effective in ensuring that patients receive the most appropriate treatment for them.”


Maria-Christina Zennaro, Inserm research professor and co-leader of HT-ADVANCE, stated: “With the launch of this European project, our objective is to use and validate multi-omics stratification biomarkers (MOMICS) for patients with hypertension to better identify those with an endocrine form, but also to predict the response to treatment in patients with primary hypertension. We expect that HT-ADVANCE will provide a step change in the management of HT by enabling a personalised, more efficient and cost-effective treatment strategy, and importantly, will prevent the ensuing cardio-metabolic complications.”


James Spargo

Related Content

No items found

Latest content